Arbor Vita Corporation

Arbor Vita Corporation focuses on developing innovative diagnostic solutions for detecting infectious diseases and cancer, specializing in rapid testing technologies that enhance healthcare providers' capabilities. Founded in 1998, Arbor Vita Corporation is based in Fremont, US. The company specializes in diagnostic solutions for infectious diseases and cancer. Its operations have remained consistent.

Arbor Vita has completed a total of 3 deals, with its most recent funding round occurring on June 28, 2006. The company raised USD 2. 000 mn in Series F funding from BD Ventures, Wilson Sonsini Goodrich & Rosati, among other investors. Arbor Vita's current company valuation is USD 85.

442 mn. Arbor Vita Corporation specializes in innovative diagnostic solutions aimed at detecting infectious diseases and cancer, with a focus on rapid testing technologies. Their notable products include the Onco E6™ Cervical Test, which detects high-risk HPV oncoproteins related to cervical cancer, and the AV Avantage™ A/H5N1 Flu Test, the only FDA-cleared rapid test for the A/H5N1 influenza virus. The Onco E6™ Cervical Test can be administered in various healthcare settings, yielding results in about two hours.

Additionally, Arbor Vita provides COVID-19 testing services with same-day results for samples submitted by 2 PM, utilizing advanced RT-PCR technology in collaboration with Yale University's SalivaDirect™ test. The company's products primarily serve healthcare providers, laboratories, and public health organizations in the United States and potential markets in regions affected by infectious diseases, including parts of Asia and Europe. Arbor Vita Corporation generates revenue through sales of its diagnostic tests, marketed directly to healthcare providers and laboratories. Their pricing structure includes efficient individual test kits such as the Onco E6™ Cervical Test and the AV Avantage™ A/H5N1 Flu Test, designed for ease of use without complex equipment.

The company engages in partnerships with healthcare facilities and government organizations to ensure access to testing solutions. Arbor Vita's products meet various client needs, contributing to a diversified revenue stream, particularly valuable during outbreaks and routine screenings. Arbor Vita Corporation aims to broaden its product offerings by designing new diagnostic tests, with specific details on release dates yet to be announced. The company plans to expand its market presence into additional regions, including specific areas in Asia and Europe, by targeting these markets in the coming years.

The recent Series F funding of USD 2. 000 mn will support these initiatives, allowing Arbor Vita to enhance its R&D capabilities and extend its reach in the healthcare market.